Milestone Pharmaceuticals (MIST) Total Liabilities (2018 - 2026)

Milestone Pharmaceuticals' Total Liabilities history runs 9 years deep, the most recent figure standing at $157.7 million for Q1 2026.

• Quarterly Total Liabilities rose 131.86% year-over-year to $157.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157.7 million (up 131.86% YoY) and the FY2025 annual result came in at $71.8 million, up 15.14% from the prior year.
• Total Liabilities was $157.7 million for Q1 2026 at Milestone Pharmaceuticals, up from $71.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $157.7 million in Q1 2026 and bottomed at $4.6 million in Q2 2022.
• A 5-year average of $54.2 million and a median of $58.5 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities declined 21.83% — and 2023, when it jumped 1120.06%.
• Milestone Pharmaceuticals' Total Liabilities stood at $8.1 million in 2022, then soared by 618.56% to $58.5 million in 2023, then grew by 6.67% to $62.4 million in 2024, then rose by 15.14% to $71.8 million in 2025, then surged by 119.64% to $157.7 million in 2026.
• Business Quant data shows MIST's Total Liabilities at $157.7 million in Q1 2026, $71.8 million in Q4 2025, and $67.2 million in Q3 2025.